Welcome to our dedicated page for Dss SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DSS, Inc. (NYSE American: DSS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, annual and quarterly filings, and other documents submitted to the U.S. Securities and Exchange Commission. These filings offer detailed information on DSS’s diversified operations in packaging, biohealth innovation, financial services, alternative trading, real estate, and other business lines, as well as its corporate governance and capital structure.
Through forms such as Form 8-K, DSS reports material events including strategic transactions, changes in auditors, debt conversion agreements, and stockholder meeting results. Examples include disclosures about a debt conversion agreement with Impact BioMedical Inc., changes in the company’s independent registered public accounting firm, and stockholder votes on director elections, auditor ratification, and executive compensation. These documents help investors understand how DSS manages its portfolio, financing arrangements, and oversight functions.
Core financial and operational details are typically found in Form 10-K annual reports and Form 10-Q quarterly reports, where DSS describes its business segments, risk factors, and financial performance across its diversified sectors. In addition, filings related to corporate actions, such as reverse stock splits or listing compliance matters, provide insight into how the company maintains its NYSE American listing and manages its capital markets presence.
On Stock Titan, DSS filings are supplemented with AI-powered summaries that highlight key points, explain complex sections in plain language, and help users quickly identify items such as auditor changes, debt conversions, and governance decisions. Real-time updates from EDGAR ensure that new DSS filings, including Forms 10-K, 10-Q, 8-K, and any insider transaction reports on Form 4, are available promptly, giving investors and researchers a structured view of the company’s regulatory history and ongoing disclosures.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a majority of the company. Mr. Chan reports beneficial ownership of 6,599,380 shares, representing 68.2% of DSS common stock based on 9,092,518 shares outstanding as of September 2, 2025. Affiliated entities include Alset Inc. (4,542,606 shares, 47.0%), Alset International Limited (1,379,943 shares, 15.2%) and Global Biomedical Pte. Ltd. (311,634 shares, 3.4%). On August 20, 2025, Alset Inc. received a $500,000 convertible promissory note convertible at $0.86 per share. On August 28, 2025, Mr. Chan sold 130,679 shares at an average price of $1.3475, in trades between $1.23 and $1.565.
Insider sale disclosed. On 08/28/2025, Heng Fai Ambrose Chan reported selling 130,679 shares of DSS, Inc. common stock at an average price of $1.3475, with trade prices ranging between $1.23 and $1.565. The Form 4 states the sale occurred in multiple trades and the reporting person undertakes to provide full trade-by-trade details upon request.
The filing reports 1,053,796 shares beneficially owned by Mr. Chan following the transaction and identifies additional holdings attributed to him: 1,002,978 shares held by Heng Fai Holdings Limited; 2,581,268 shares held by Alset Inc.; a $500,000 convertible promissory note held by Alset Inc.; 1,068,309 shares held by Alset International Limited; and 311,634 shares held by Global Biomedical Pte. Ltd. The Form 4 is signed 09/02/2025.
DSS, Inc. amended a Form 4 to clarify insider transactions and disclose that on August 20, 2025 the company issued a $500,000 convertible promissory note to Alset Inc. The note allows Alset Inc. to convert principal and accrued interest into common stock at a conversion price of $0.86 per share, or to exchange into any subsequently issued convertible instrument on different terms based on the note balance plus accrued interest. The filing details the beneficial ownership attributable to reporting person Heng Fai Ambrose Chan, including shares held directly and through affiliated entities totaling disclosed positions across Heng Fai Holdings Limited, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd., and notes the convertible note is exercisable through July 31, 2028.
DSS, Inc. insider transaction summary: On 08/20/2025 the company issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The stated conversion would equate to 581,395 shares.
Reporting person and ownership: The filing is by Heng Fai Ambrose Chan and Alset Inc.; Mr. Chan is identified as a director and a greater-than-10% owner. The filing discloses Mr. Chan's total beneficial ownership of 6,730,059 shares, detailed by holdings across Heng Fai Holdings Limited, direct holdings, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a large majority of the company’s common stock. Together they beneficially own 6,730,059 shares, representing 69.6% of the 9,092,518 shares outstanding as of August 21, 2025. Alset Inc. alone holds 4,542,606 shares (47.0%). On August 20, 2025, DSS issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The filing lists the ownership breakdown across Heng Fai Holdings Limited, Alset entities and Global Biomedical, and cites a joint filing agreement as an exhibit.